Pharmaceutical Business review

CHMP recommends marketing authorization for Astellas’s antimycotic drug

The active substance of Mycamine is micafungin, an antimycotic for systemic use. The benefits with Mycamine are its clinical and microbiological cure and prophylaxis of Candida infection. The most common side effects are vomiting, nausea and diarrhoea and elevated liver enzymes.